Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMV3L62)

Drug Name
Sym023 Drug Info
Indication
Disease Entry ICD 11 Status REF
Lymphoma 2A80-2A86 Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMV3L62

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Hepatitis A virus cellular receptor 2 (TIM3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MBG453 DMBPY9Z Myelodysplastic syndrome 2A37 Phase 3 [3]
RO7121661 DM8A120 Esophageal squamous cell carcinoma 2E60.1 Phase 2 [4]
GSK4069889 DMV6SNU Non-small-cell lung cancer 2C25 Phase 2 [5]
AZD7789 DMOIHWI Hodgkin lymphoma 2B30 Phase 2 [6]
TB006 DMKN524 Alzheimer disease 8A20 Phase 2 [7]
BGB-A425 DMI42Q0 Non-small-cell lung cancer 2C25 Phase 1/2 [8]
LY3415244 DM5QO1A Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
LY3321367 DMD51GC Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
INCAGN2390 DM5SO1T Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hepatitis A virus cellular receptor 2 (TIM3) TT1RWL7 HAVR2_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03489343) Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Symphogen.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
5 Clinical pipeline report, company report or official report of GlaxoSmithKline.
6 Clinical pipeline report, company report or official report of AstraZeneca
7 Clinical pipeline report, company report or official report of TrueBinding
8 Clinical pipeline report, company report or official report of BeiGene.
9 Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 May 15;27(10):2773-2781.
10 Clinical pipeline report, company report or official report of Agenus.